Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
04 Feb 2016 EMA Adopts a New Indication for Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2016 Reshaping the Cancer Clinic Personalised medicine
02 Feb 2016 FDA Approves Eribulin Mesylate for the Treatment of Unresectable or Advanced Liposarcoma Sarcomas - Anticancer agents & Biologic therapy
01 Feb 2016 EMA Recommends Granting a Marketing Authorisation for Elotuzumab Haematologic malignancies - Anticancer agents & Biologic therapy
29 Jan 2016 Cancer in China Epidemiology/Etiology/Cancer Prevention
28 Jan 2016 FDA Extends Indications for Ofatumumab in CLL Haematologic malignancies - Anticancer agents & Biologic therapy
27 Jan 2016 Nivolumab plus Ipilimumab Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status Melanoma - Cancer Immunology and Immunotherapy
27 Jan 2016 Annals of Oncology Press Release: Important falls in death rates from leukaemia in Europe predicted for 2016 Haematologic malignancies
07 Jan 2016 New NICE Guidelines to Improve End of Life Care Palliative and supportive care
21 Dec 2015 European Medicines Agency Recommends Two New Indications for Ramucirumab Lung and other thoracic tumours - Gastrointestinal cancers - Anticancer agents & Biologic therapy
21 Dec 2015 European Medicines Agency Recommends Granting a Conditional Marketing Authorisation for Osimertinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Dec 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Necitumumab Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Dec 2015 European Medicines Agency Recommends to Extend Therapeutic Indications for Erlotinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Dec 2015 Trastuzumab-emtansine Too Costly for Use on the NHS England Breast cancer - Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
20 Dec 2015 ESMO Asia 2015 News: RADIANT-4 Supports Everolimus in Neuroendocrine Tumour Patients Gastrointestinal cancers